The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

M Ducreux; G K Abou-Alfa; T Bekaii-Saab; J Berlin; A Cervantes; T de Baere; C Eng; P Galle; S Gill; T Gruenberger; K Haustermans; A Lamarca; P Laurent-Puig; J M Llovet; F Lordick; T Macarulla; D Mukherji; K Muro; R Obermannova; J-M O'Connor; E M O'Reilly; P Osterlund; P Philip; G Prager; E Ruiz-Garcia; B Sangro; T Seufferlein; J Tabernero; C Verslype; H Wasan; E Van Cutsem

doi:10.1016/j.esmoop.2023.101567

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

ESMO Open. 2023 Jun;8(3):101567. doi: 10.1016/j.esmoop.2023.101567. Epub 2023 May 31.

Authors

M Ducreux¹, G K Abou-Alfa², T Bekaii-Saab³, J Berlin⁴, A Cervantes⁵, T de Baere⁶, C Eng⁴, P Galle⁷, S Gill⁸, T Gruenberger⁹, K Haustermans¹⁰, A Lamarca¹¹, P Laurent-Puig¹², J M Llovet¹³, F Lordick¹⁴, T Macarulla¹⁵, D Mukherji¹⁶, K Muro¹⁷, R Obermannova¹⁸, J-M O'Connor¹⁹, E M O'Reilly²⁰, P Osterlund²¹, P Philip²², G Prager²³, E Ruiz-Garcia²⁴, B Sangro²⁵, T Seufferlein²⁶, J Tabernero²⁷, C Verslype¹⁰, H Wasan²⁸, E Van Cutsem¹⁰

Affiliations

¹ Université Paris-Saclay, Gustave Roussy, Villejuif, France. Electronic address: michel.ducreux@gustaveroussy.fr.
² Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA; Trinity College Dublin, Dublin, Ireland.
³ Mayo Clinic Cancer Center, Phoenix.
⁴ Vanderbilt-Ingram Cancer Center, Nashville, USA.
⁵ INCLIVA, Biomedical Research Institute, Hospital Clínico Universitario, University of Valencia, Valencia, Spain.
⁶ Université Paris-Saclay, Gustave Roussy, Villejuif, France.
⁷ University Medical Center Mainz, Mainz, Germany.
⁸ BC Cancer/University of British Columbia, Vancouver, Canada.
⁹ Clinic Favoriten, HPB Center Health Network Vienna and Sigmund Freud University, Medical School, Vienna, Austria.
¹⁰ University Hospitals Gasthuisbergs, Leuven; Katholieke Universiteit Leuven, Leuven, Belgium.
¹¹ Department of Oncology, OncoHealth Institute, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Medical Oncology, The Christie NHS Foundation, Manchester; Division of Cancer Sciences, University of Manchester, Manchester, UK.
¹² Institut du cancer Paris CARPEM, APHP, Georges Pompidou Hospital, Université Paris Cité, Paris, France.
¹³ Icahn School of Medicine at Mount Sinai, Mount Sinai Liver Cancer Program, New York, USA; Institut d'Investigacions Biomèdiques August Pi i Sunyer Hospital Clínic, Universitat de Barcelona, Barcelona; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain.
¹⁴ University of Leipzig Medical Center, Comprehensive Cancer Center Central Germany, Leipzig, Germany.
¹⁵ Vall d'Hebron Hospital Campus, Barcelona, Spain; Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain.
¹⁶ American University of Beirut, Beirut, Lebanon.
¹⁷ Aichi Cancer Center Hospital, Nagoya, Japan.
¹⁸ Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
¹⁹ Instituto Alexander Fleming, Buenos Aires, Argentina.
²⁰ Memorial Sloan Kettering Cancer Center, New York; Weill Cornell College of Medicine, New York, USA.
²¹ Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden; Tampere University Hospital, University of Tampere, Tampere, Finland.
²² Henry Ford Cancer Institute, Departments of Oncology and Pharmacology, Wayne State University, Detroit, USA.
²³ Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
²⁴ Instituto Nacional de Cancerologia, Mexico, Mexico.
²⁵ Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain.
²⁶ Ulm University Hospital, Ulm, Germany.
²⁷ Vall d'Hebron Hospital Campus and Institute of Oncology, IOB-Quiron, UVic-UCC, Barcelona, Spain.
²⁸ Hammersmith Hospital, Imperial College London, London, UK.

Abstract

This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is mandatory to ensure an optimal diagnosis and staging of HCC, planning of curative and therapeutic options, including surgical, embolisation, ablative strategies, or systemic therapy. Furthermore, in many patients with HCC, underlying liver cirrhosis represents a challenge and influences the therapeutic options.

Keywords: chemoembolisation; hepatocellular carcinoma; immunotherapy; liver transplantation; radioembolisation.

Publication types

Review

MeSH terms

Carcinoma, Hepatocellular* / diagnosis
Carcinoma, Hepatocellular* / therapy
Gastrointestinal Neoplasms* / diagnosis
Gastrointestinal Neoplasms* / therapy
Humans
Liver Neoplasms* / diagnosis
Liver Neoplasms* / therapy
Practice Guidelines as Topic

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States